论文部分内容阅读
目的 :观察拉米夫定对乙肝肝硬化失代偿期伴脾亢患者的疗效与安全性。方法 :对 18例乙肝肝硬化失代偿期伴脾亢患者 ,在其肝炎活动期 ,以拉米夫定每天 10 0 mg口服 ,总疗程以 HBV DNA阴转、HBe Ag血清转换后再服 3～ 6个月为准。以 HBV DNA阴转与 HBe Ag血清转换、肝炎活动控制与肝硬化分级变化作评估指标 ,考核治疗组与配对对照组于服药 1年与完成疗程后随访 1年的疗效与安全性。结果 :治疗组该二期总疗程有效率分别为 2 7.77%与 71.4 3% ,安全性良好。结论 :拉米夫定对非注册性适应症 -乙肝肝硬化失代偿期伴脾亢患者同样有良好疗效与安全性
Objective: To observe the efficacy and safety of lamivudine in patients with decompensated hepatitis B and hypersplenism. Methods: 18 patients with decompensated hepatitis B cirrhosis with hypersplenism were given orally 100 mg lamivudine daily for the duration of hepatitis. The total course of treatment was HBV DNA negative conversion and HBeAg seroconversion before taking 3 ~ 6 months prevail. Hepatitis B virus conversion and HBeAg seroconversion, hepatitis activity control and liver cirrhosis grading changes for the assessment of indicators to assess the treatment group and the matched control group after taking medicine for 1 year and complete follow-up after treatment for 1 year efficacy and safety. Results: The effective rate of the second phase of the treatment group was 2 7.77% and 71.4 3%, respectively, with good safety. Conclusions: Lamivudine also has good efficacy and safety in non-registration indications - decompensated hepatitis B patients with hypersplenism